Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

Trial Profile

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

Phase of Trial: Phase I/II

Latest Information Update: 03 Jul 2015

At a glance

  • Drugs Mocetinostat (Primary) ; Gemcitabine
  • Indications Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors MethylGene
  • Most Recent Events

    • 12 May 2009 Additional lead trial investigator Martell R identified as reported by ClinicalTrials.gov.
    • 16 Dec 2008 Status changed from suspended to completed as reported by Clinicaltrials.gov
    • 22 Sep 2008 Planned end date changed from 1 Dec 2008 to 1 Dec 2009, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top